NCT06961721View on ClinicalTrials.gov

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions
Prevention of Herpes Zoster
Interventions
BIOLOGICAL

Herpes Zoster Vaccine, Live

assigned to the vaccine group and placebo group in a 2:1 ratio.

BIOLOGICAL

Placebo

assigned to the vaccine group and placebo group in a 2:1 ratio.

Sponsors
All Listed Sponsors
collaborator

Inner Mongolia Center for Disease Control and Prevention

UNKNOWN

collaborator

Center for Disease Control and Prevention, Fujian

OTHER

lead

Changchun BCHT Biotechnology Co.

INDUSTRY

NCT06961721 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older | Biotech Hunter | Biotech Hunter